Allakos Inc
ALLK
Company Profile
Business description
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Contact
825 Industrial Road
Suite 500
San CarlosCA94070
USAT: +1 650 597-5002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
131
Stocks News & Analysis
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
stocks
Megatrend Investing: ASX players to capitalise on the clean energy transition
Find out how you can benefit from global megatrends.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,683.40 | 55.00 | 0.64% |
| CAC 40 | 7,883.61 | 22.79 | -0.29% |
| DAX 40 | 21,532.77 | 27.07 | 0.13% |
| Dow JONES (US) | 44,579.93 | 158.02 | 0.36% |
| FTSE 100 | 8,602.56 | 31.79 | 0.37% |
| HKSE | 20,597.09 | 192.87 | -0.93% |
| NASDAQ | 19,546.63 | 107.38 | -0.55% |
| Nikkei 225 | 38,831.48 | 33.11 | 0.09% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,026.38 | 11.50 | -0.19% |
| S&P/ASX 200 | 8,416.90 | 37.50 | 0.45% |
| SSE Composite Index | 3,229.49 | 21.11 | -0.65% |